Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed as Formula (I).

Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.

Abstract: The present invention relates to a new compound of salvianolic acid L, its preparation method, a pharmaceutical composition containing the salvianolic acid L, and its use for preparing a medicament for treating cardio-cerebrovascular diseases.

Abstract: A method for inhibiting the crystal growth rate of an amide compound present in a molten polyolefin-based resin and a method for producing a polyolefin-based resin molded article are provided. A phenol compound is incorporated into an amide compound-containing polyolefin-based resin such that a weight ratio, amide compound:phenol compound, is 60:40 to 10:90.

Abstract: Esters of O-substituted hydroxy carboxylic acids are provided having Formula 1, or 2, or both Formulas 1 and 2: wherein R and R1 are independently selected from the group consisting of substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1-C22 alkyl, substituted and unsubstituted C3-C8 cycloalkyl, substituted and unsubstituted C6-C20 carbocyclic aryl, and substituted and unsubstituted C4-C20 heterocyclic; wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and wherein n is 1-6. Process of producing esters of O-substituted hydroxy carboxylic acids are also provided.

Abstract: The present invention relates to the use of compounds of the formula (I), with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

Abstract: The present invention relates to novel trifluoromethoxyphenyl-substituted tetramic acid derivatives of the formula (I), in which J, X, Y, A, B, D and G have the meanings given above, to a number of processes for their preparation, and to their use as pesticides and/or herbicides. The invention further provides selective herbicidal compositions which comprise, firstly, trifluoromethoxyphenyl-substituted tetramic acid derivatives and, secondly, a crop plant compatibility-improving compound. The invention further relates to the boosting of the action of crop protection compositions comprising compounds of the formula (I) through the additions of ammonium salts or phosphonium salts and optionally penetrants.

Abstract: Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): (wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONR5R6; R5 and R6 are each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid ? peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid ? peptide aggregate.

Abstract: The subject of the present invention is a method for separating phenolic compounds in salified form from a reaction medium comprising them. The method of the invention for separating phenolic compounds in salified form from an aqueous reaction medium resulting from the reaction of a phenolic compound and of glyoxylic acid in the presence of a base leading to a reaction medium comprising at least the excess of initial phenolic compound in salified form and the various mandelic compounds in salified form resulting from the reaction, is characterized by the fact that said reaction medium is brought into contact with a basic anion-exchange resin that leads to the selective attachment of the initial phenolic compound to said resin and to the recovery of an aqueous stream comprising the mandelic compounds in salified form resulting from the reaction, and that the phenolic compound in salified form attached to the resin is separated by a resin regeneration treatment.

Abstract: The invention relates to novel 2,4,6-phenyl-substituted cyclic ketoenols of the formula (I), in which CKE, W, X and Y are as defined above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, and also to selective herbicidal compositions comprising firstly the 2,4,6-phenyl-substituted cyclic ketoenols and secondly at least one compound which improves crop plant tolerance.

Abstract: A novel manufacturing process is described for producing hindered phenolic alkyl esters, which may be useful as antioxidants. This process simplifies catalyst neutralization and removal during the preparation of hindered phenolic esters. Compositions that comprise the hindered phenolic esters produced according to these methods are also described.

Abstract: The present invention relates to the use of a compound of Formula (I??) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.

Abstract: The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

Abstract: The invention relates chemical compound entry inhibitors and methods of determining such inhibitors that interact with regions of viruses, such as the dengue virus, as candidates for in vivo anti-viral compounds.

Abstract: A biologically active agent, wherein the agent is a compound of the formula: Wherein A, R5, R9, X, Q and n, m, q are defined herein below.

Abstract: Compositions and methods for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting bone growth or for the maintenance of bone health and methods regarding same. In an embodiment, the present invention provides a composition comprising an active ingredient having an effective amount of a plant or plant extract containing at least one phytochemical having the ability to induce bone morphogenic protein expression.

Abstract: Novel 3-phenylpropanoic acid compounds have the general formula (I) below: and are formulated into pharmaceutical compositions for administration in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or lipid metabolism-related diseases), or, alternatively, into cosmetic compositions.

Abstract: A method of producing a compound represented by the following general formula (3): [wherein R is a bivalent aliphatic group having a carbon number of 1-16 or a bivalent aromatic group], which comprises a step (i) of reacting a compound represented by the following general formula (1): with a carboxylic acid halide represented by the following general formula (2): [wherein R is a bivalent aliphatic group having a carbon number of 1-16 or a bivalent aromatic group and X is a halogen atom] in the presence of a basic compound to form an ester, and a step (ii) of conducting a heat treatment after the step (i) to decompose an oligomer in the ester.

Abstract: The present invention relates to new classes of monomeric compounds, which may be polymerized to form novel biodegradable and bioresorble polymers and co-polymers. These polymers and co-polymers, while not limited thereto, may be adapted for radioopacity and are useful for medical device applications and controlled release therapeutic formulations.

Abstract: Resveratrol ferulate compounds and compositions.

Abstract: This disclosure describes the molecular cloning of a pactamycin biosynthetic gene cluster from Streptomyces pactum ATCC 27456, characterization of individual genes in the gene cluster and the proteins encoded thereby as well as uses thereof. The pactamycin gene cluster is located within an 86.35 kilobases genetic locus and includes 53 open reading frames, 26 of which are considered to be the core cluster directly involved in the biosynthesis of pactamycin.

Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Abstract: The present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof. More particularly, the present invention relates to a transglutaminase inhibitor comprising chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof which effectively inhibits the activity of transglutaminase, the overexpression of which is responsible for the etiology of various diseases, and to novel uses thereof. The present invention provides a transglutaminase inhibitor and a method of inhibiting transglutaminase, both of which are based on using chlorogenic acid, a pharmaceutically acceptable salt thereof, or a derivative thereof as an active ingredient.

Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

Abstract: The present invention relates to a norbornene monomer, a polynorbornene derivative, a liquid crystal alignment film including the same, and a liquid crystal display device including the same. More particularly, the present invention relates to a norbornene monomer, a polynorbornene derivative, a liquid crystal alignment film including the same, and a liquid crystal display device including the same, which have an alignment property by photoreaction, excellent thermal stability and photoreactivity, the increased photo-reaction rate and reliability of the alignment film, thereby showing high manufacturing process efficiency.

Abstract: A novel manufacturing process is described for producing hindered phenolic alkyl esters, which may be useful as antioxidants. This process simplifies catalyst neutralization and removal during the preparation of hindered phenolic esters. Compositions that comprise the hindered phenolic esters produced according to these methods are also described.

Abstract: Described is the use of specific merocyanine derivatives for protecting body-care and household products from photolytic and oxidative degradation. These compounds perform outstanding UV absorber properties.

Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.

Abstract: The present invention relates to an improved process for the preparation of phenolic carboxylic acid derivatives catalysed by biocatalytic esterification, transesterification or amidation of a corresponding lower alkyl ester. Biocatalysis is performed in the presence of suitable enzymes, e.g. hydrolases, especially esterases, amidases, lipases and proteases.

Abstract: The invention relates to a process for preparing solid particles comprising a phenolic antioxidant in essentially crystalline form and to the process step of further processing the phenolic antioxidants. Solid particles are prepared from a melt of the phenolic antioxidants are added to a dispersion comprising the solid particles of the compound (I) in a mixture of an organic water-miscible solvent and water and the crystals obtained from the dispersion are separated.

Abstract: A process for preparing 3,5,5-Trimethyl-2-cyclohexene salicylate includes the reacting of 2-hydroxybenzoic acid with 3,5,5-Trimethyl-2-cyclohexen-1-ol in the presence of a coupling reagent.

Abstract: Carbonyl compounds of the formula (II), wherein R1 and R2 are as defined herein, react in the presence of an amine with carboxylic acid derivatives of the formula (II), wherein R3 and EWG are also as defined herein, to give ?,?-unsaturated compounds of the formula (I) according to the following scheme: It is possible under mild reaction conditions to obtain unsaturated esters with high (E) stereoselectivity. The reaction typically proceeds at room temperature or lower without particular requirements such as inert gas, exclusion of moisture, heat, etc., being made. The only by-products obtained are CO2 and water.

Abstract: Method for the preparation of ester compounds for use as skin brightening agents and compositions for brightening skin containing the ester compounds.

Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.

Abstract: The present invention relates, inter alia, to a process for preparing a compound of formula (I): which comprises either (a) reacting a compound of formula (II): with 2-cyanophenyl, or a salt thereof, in the presence of between 0.1 and 2 mol % of 1,4-diazabicyclo[2.2.2]octane, or (b) reacting a compound of the formula (III): with a compound of the formula (IV): in the presence of between 0.1 and 2 mol % of 1,4-diazabicyclo[2.2.2]octane; where W is the methyl (E)-2-(3-methoxy)acrylate group C(CO2CH3)?CHOCH3 or the methyl 2-(3,3-dimethoxy)propanoate group C(CO2CH3)CH(OCH3)2, or a mixture of the two groups. In addition, the present invention relates to a novel precursors of the compound of formula (I) and methods for making them.

Abstract: The invention relates to a hydroxy-aromatic compound of formula (I): wherein: at least one of the set consisting of R1, R3, and R5 is a group of formula (II); any remaining one or two of the set consisting of R1, R3, and R5 being H, OH, a C1-C12 alkyl group or an oligomeric or polymeric system; R2 and R4 are H, OH, a C1-C12 alkyl group or an oligomeric or polymeric system; formula (II) is the following group: wherein EWG is an electron-withdrawing group.

Abstract: The present invention relates to the use of compounds of the formula (I), with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

Abstract: A method of making a hindered phenolic antioxidant is disclosed wherein the method comprises: reacting an ester of the formula: wherein R1, R2, and R3 are independently selected alkyl groups and n is 0, 1, or 2, with an aliphatic polyhydroxyl alcohol of the general formula R(OH)n wherein R is an aliphatic group of from 2 to about 12 carbon atoms and n is an integer of from 2 to 7, provided that one hydroxyl is primary and the others are secondary or tertiary, in the presence of a strong acid catalyst; then, neutralizing the strong acid catalyst with an overbased detergent; and isolating the hindered phenolic antioxidant after the neutralization step.

Abstract: The invention relates to a process for preparing solid particles of a phenolic antioxidant from the IRGANOX series in the form of crystals, particularly IRGANOX 1010 and 1098, the crystal particles obtainable by the process, the further processing of the crystal particles, an aqueous dispersion comprising the phenolic antioxidant, novel crystal modifications of pentaerythritol tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate] (?-form) and N,N?-hexane-1,6diyl-bis[3-(3,5-di-tert-butyl-4-hydroxypheylpropamide)] (?-form) and aqueous dispersion comprising the new crystal modifications.

Abstract: The invention provides substituted phenol compounds and pharmaceutical compositions containing substituted phenol compounds which are useful for inducing or maintaining anesthesia or sedation in a mammal. This invention also provides methods for inducing or maintaining anesthesia or sedation in a mammal using substituted phenol compounds.

Abstract: According to the invention, there is provided a novel 3,4-dihydroxyhydrocinnamic acid derivative, designated DHH105, having blood glucose lowering effects in vivo as a result of the enhancement of glucose transport mediated by the increase of insulin receptor signaling. This invention thus relates to a 3,4-dihydroxyhydrocinnamic acid derivative useful as an anti-diabetic agent, represented by the following formula I: or pharmaceutically acceptable salts thereof, to a method for preparing the compound, and to a composition for treating diabetes comprising the same as an active ingredient.

Abstract: To provide a liquid crystalline compound capable of exhibiting a biaxial liquid crystal phase, provide a trifunctional or greater functional polymerizable liquid crystalline compound having polymerizable groups, and also to provide a liquid crystalline composition and a retardation film which are using the liquid crystalline compound, a compound and a liquid crystalline compound each are represented by formula (I) defined in the specification; a liquid crystalline composition contains the compound; and a retardation film has an optically anisotropic layer formed from the compound.

Abstract: A class of UVA- and UVB-absorbing esters has been derived by modifying hydroxy triglycerides and other acyltriglycerides with any of a variety of cinnamic acids. The esterification reactions are preferably conducted at elevated temperatures without a catalyst. The resultant agents have the advantage of being synthesized from natural materials, while providing a value-added use for the oil. They are readily formulated into standard UV-absorbing daily-wear cosmetic, hair and skin care, and sunscreen formulations.

Abstract: The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), a method for the preparation of said compounds by cultivation of the fungus Cryphonectria parasitica, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's Disease, Parkinson's Disease, Huntington's Diseases, stroke, psychosis and/or depressions.

Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Abstract: The invention relates to stabilizers containing at least two phenolic groups bonded to one another via a connecting radical (II) which is a polyol with a number-average molecular weight of from 75×F g/mol to 250×F g/mol, preferably from 100×F g/mol to 200×F g/mol, in particular from 100×F g/mol to 150×F g/mol, where the term F is the number of phenolic groups in the molecule.

Abstract: Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.

Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Abstract: The invention provides methods for treating beta-Amyloid protein-induced disease, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural product compounds isolated from turmeric, gingko biloba, and ginger, and synthetic chemical analogues thereof, for the treatment of a beta-Amyloid protein-induced disease.